Collaborating to Move Research Forward: Proceedings of the 10th Annual Bladder Cancer Think Tank

The 10th Annual Bladder Cancer Think Tank was hosted by the Bladder Cancer Advocacy Network and brought together a multidisciplinary group of clinicians, researchers, representatives and Industry to advance bladder cancer research efforts. Think Tank expert panels, group discussions, and networking opportunities helped generate ideas and strengthen collaborations between researchers and physicians across disciplines and between institutions. Interactive panel discussions addressed a variety of timely issues: 1) data sharing, privacy and social media; 2) improving patient navigation through therapy; 3) promising developments in immunotherapy; 4) and moving bladder cancer research from bench to bedside. Lastly, early career researchers presented their bladder cancer studies and had opportunities to network with leading experts.

[1]  G. Sonpavde,et al.  Impact of gemcitabine + cisplatin + ipilimumab on circulating immune cells in patients (pts) with metastatic urothelial cancer (mUC). , 2015 .

[2]  J. Lunceford,et al.  Pembrolizumab (MK-3475) for advanced urothelial cancer: Updated results and biomarker analysis from KEYNOTE-012. , 2015 .

[3]  E. Small,et al.  Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab , 2015, Cancer Immunology Research.

[4]  Steven L. Chang,et al.  Improving selection criteria for early cystectomy in high-grade t1 bladder cancer: a meta-analysis of 15,215 patients. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  P. Hegde,et al.  MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.

[6]  E. Messing,et al.  Estrogen receptor alpha prevents bladder cancer via INPP4B inhibited akt pathway in vitro and in vivo. , 2014 .

[7]  S. Gabriel,et al.  Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. , 2014, Cancer discovery.

[8]  Anirban P. Mitra,et al.  Enhanced recovery protocol after radical cystectomy for bladder cancer. , 2014, The Journal of urology.

[9]  Antoni Ribas,et al.  Improved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients , 2014, Science Translational Medicine.

[10]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.

[11]  M. Menon,et al.  Is there a relationship between leapfrog volume thresholds and perioperative outcomes after radical cystectomy? , 2014, Urologic oncology.

[12]  S. Daneshmand,et al.  Incidence and location of lymph node metastases in patients undergoing radical cystectomy for clinical non-muscle invasive bladder cancer: results from a prospective lymph node mapping study. , 2014, Urologic oncology.

[13]  The Cancer Genome Atlas Research Network,et al.  Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.

[14]  David C. Miller,et al.  Practice based collaboration to improve the use of immediate intravesical therapy after resection of nonmuscle invasive bladder cancer. , 2013, The Journal of urology.

[15]  Huanming Yang,et al.  Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation , 2013, Nature Genetics.

[16]  S. Daneshmand.  Determining the role of cystectomy for high-grade T1 urothelial carcinoma. , 2013, The Urologic clinics of North America.

[17]  G. Sonpavde,et al.  Current Preclinical Models for the Advancement of Translational Bladder Cancer Research , 2012, Molecular Cancer Therapeutics.

[18]  M. Albert,et al.  Preexisting BCG-Specific T Cells Improve Intravesical Immunotherapy for Bladder Cancer , 2012, Science Translational Medicine.

[19]  Shahrokh F. Shariat,et al.  Loss of the Urothelial Differentiation Marker FOXA1 Is Associated with High Grade, Late Stage Bladder Cancer and Increased Tumor Proliferation , 2012, PloS one.

[20]  Jedd D. Wolchok,et al.  Immunologic correlates of the abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.

[21]  Qiuling Shi,et al.  Automated symptom alerts reduce postoperative symptom severity after cancer surgery: a randomized controlled clinical trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  R. Tibshirani,et al.  In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  T. Sun,et al.  Deficiency of pRb family proteins and p53 in invasive urothelial tumorigenesis. , 2009, Cancer research.

[24]  C. Cordon-Cardo,et al.  Inactivation of p53 and Pten promotes invasive bladder cancer. , 2009, Genes & development.

[25]  D. Gillatt,et al.  Introduction of an enhanced recovery protocol for radical cystectomy , 2008, BJU international.

[26]  W. Otto,et al.  Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach? , 2008, European urology.

[27]  C. Cordon-Cardo,et al.  Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. , 2007, The Journal of clinical investigation.

[28]  A. Orsola,et al.  Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. , 2005, European urology.

[29]  S. H. Hoption Cann,et al.  Dr William Coley and tumour regression: a place in history or in the future. , 2003, Postgraduate medical journal.

[30]  T. Sun,et al.  Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation , 2001, Oncogene.

[31]  M. O'Donnell,et al.  BCG immunotherapy of bladder cancer: 20 years on , 1999, The Lancet.

[32]  D. Raghavan,et al.  Magnetic resonance imaging of response to chemotherapy in orthotopic xenografts of human bladder cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  G. Cunha,et al.  The possible influence of temporal factors in androgenic responsiveness of urogenital tissue recombinants from wild-type and androgen-insensitive (Tfm) mice. , 1978, The Journal of experimental zoology.

[34]  Mole Rh.  Whole body irradiation; radiobiology or medicine? , 1953 .

[35]  R. Mole.  Whole body irradiation; radiobiology or medicine? , 1953, The British journal of radiology.